Yong-Ho Lee Yong-Ho Lee (Yonsei University, Korea) | SS1 Novel DPP-4 inhibitor; anagliptin which improve hyperglycemia and ameliorate arterial stiffness |
Chong Hwa Kim Sejong General Hospital, Korea | SS2 Update on the safety of SGLT-2 inhibitor in elderly type 2 diabetes patients; focusing on ipragliflozin’s final analysis of STELLA-ELDER |
Suk Chon Kyung Hee University, Korea | SS3 The latest updates in the management of dyslipidemia in the diabetes mellitus: what to consider what not |
Mi Kyung Kim Inje University, Korea | SS4 Benefit your T2DM patients by early initiation of metformin/SGLT-2I combination treatment |
Roger Chen Concord Repatriation General Hospital, Australia | SS5 SWITCH: the answer to better glycaemic control safely |
Kyu Yeon Hur Sungkyunkwan University, Korea | SS6 Advances in the treatment of type 2 diabetes: a new once-weekly GLP-1 receptor agonist, dulaglutide |
Sung Hoon Yu Hanyang University, Korea | SS7 Empagliflozin: deep diving into EMPA-REG outcome(CV & renal) |
Young Min Cho Seoul National University, Korea | SS8 Practical insulin titration: let your patient take the helm |
Eun-Gyoung Hong Hallym University, Korea | SS9 A new and powerful treatment option for dyslipidemia in type 2 diabetes mellitus |
Kyung Mook Choi Korea University, Korea | SS10 New anti-obesity drug |
Soo Lim Seoul National University, Korea | SS11 The optimized DPP-4 inhibitor for type 2 diabetes: focus on recent clinical results of gemigliptin in Korea |
Jae Hyuk Lee Seonam University, Korea | SS12 Efficacy and safety of lobeglitazone / metformin combination therapy in T2DM patients |
Hyuk-Sang Kwon The Catholic University of Korea, Korea | SS13 CV outcomes of alogliptin in T2DM patients: from free of CVD history to the highest-CV risk |
Jong Chul Won Inje University, Korea | SS14 Efficacy and safety of the new DPP-4 inhibitor evogliptin |